1. Amyotrophic lateral sclerosis: from pathological mechanisms to patient care

   • G. Scarlato

   Foreword Pages: S1 - S2

2. Glutamate, excitotoxicity and amyotrophic lateral sclerosis

   • P. J. Shaw
   • P. G. Ince

   OriginalPaper Pages: S3 - S14

3. Transgenic animal models of familial amyotrophic lateral sclerosis

   • Mark E. Gurney

   OriginalPaper Pages: S15 - S20

4. The amyotrophic lateral sclerosis health state scale and the effect of riluzole

   • T. L. Munsat

   BriefCommunication Pages: S21 - S21

5. The Riluzole Early Access Programme: descriptive analysis of 844 patients in France

   • Vincent Meininger
   • Michel Dib
   • Philippe Zeisser

   OriginalPaper Pages: S22 - S25

6. Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis

   • Michael Swash

   OriginalPaper Pages: S26 - S29

7. Impact of riluzole on the relationship between patient and physician

   • R. Dengler
   • M. Tröger

   OriginalPaper Pages: S30 - S32

8. Concluding remarks

   • G. Scarlato

   BriefCommunication Pages: S33 - S33

9. Announcements

   Announcement Pages: S34 - S34